Use of Immunosuppression, Romiplostim, and Splenectomy to Achieve Remission in a British Shorthair Cat With Primary Immune-Mediated Thrombocytopenia
- PMID: 40525770
- PMCID: PMC12172128
- DOI: 10.1111/jvim.70149
Use of Immunosuppression, Romiplostim, and Splenectomy to Achieve Remission in a British Shorthair Cat With Primary Immune-Mediated Thrombocytopenia
Abstract
A 2-year-old female spayed British Shorthair cat was diagnosed with immune-mediated thrombocytopenia (ITP) after presenting with a 3-week history of gastrointestinal bleeding and anemia. Treatment with an immunosuppressive dose of glucocorticoids was initiated, but relapse occurred within 3 weeks. Because of persistent thrombocytopenia and recurrence of clinical signs of active bleeding, despite further treatment with chlorambucil, romiplostim, and subsequently splenectomy and mycophenolate mofetil was used to successfully treat the cat for 6 months. This case describes the first known use of romiplostim for the treatment of ITP in a cat and demonstrates that although the efficacy of sustained romiplostim use might be variable, it might be effective in treating life-threatening thrombocytopenia while alternative treatments are pursued.
Keywords: ITP; platelets; splenectomy; thrombopoiesis; thrombopoietin.
© 2025 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.J Med Econ. 2012;15(5):956-76. doi: 10.3111/13696998.2012.688902. Epub 2012 May 23. J Med Econ. 2012. PMID: 22533524
-
[Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France].Transfus Clin Biol. 2014 May;21(2):85-93. doi: 10.1016/j.tracli.2014.03.007. Epub 2014 May 3. Transfus Clin Biol. 2014. PMID: 24797790 French.
-
The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering.Br J Haematol. 2025 Jun;206(6):1743-1753. doi: 10.1111/bjh.20100. Epub 2025 May 19. Br J Haematol. 2025. PMID: 40384450 Clinical Trial.
-
Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment.Blood Rev. 2024 Sep;67:101222. doi: 10.1016/j.blre.2024.101222. Epub 2024 Jun 20. Blood Rev. 2024. PMID: 38942688 Review.
-
Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.Blood Coagul Fibrinolysis. 2012 Jun;23(4):331-4. doi: 10.1097/MBC.0b013e3283513a97. Blood Coagul Fibrinolysis. 2012. PMID: 22343685
References
-
- Wondratschek C., Weingart C., and Kohn B., “Primary Immune‐Mediated Thrombocytopenia in Cats,” Journal of the American Animal Hospital Association 46, no. 1 (2010): 12–19. - PubMed
-
- Tasker S., Mackin A. J., and Day M. J., “Primary Immune‐Mediated Thrombocytopenia in a Cat,” Journal of Small Animal Practice 40, no. 3 (1999): 127–131. - PubMed
-
- Garon C., Scott M., Selting K., et al., “Idiopathic Thrombocytopenic Purpura in a Cat,” Journal of the American Animal Hospital Association 35, no. 6 (1991): 464–470. - PubMed
-
- Best M. and Fry D., “Primary Immune‐Mediated Thrombocytopenia and Immune‐Mediated Neutropenia Suspected in a 21‐Week‐Old Maine Coon Cat,” Australian Veterinary Journal 92, no. 7 (2014): 250–253. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous